CAR T-cell therapy: Canadian patient in landmark trial shares his story
Owen Snider was given as little as three months to live. His blood cancer had returned and the prognosis was not good. The news, delivered over the phone during the height of the early pandemic lockdown in spring 2020, was devastating.
The Ottawa-area retiree began putting his affairs in order, preparing for what appeared to be inevitable.
“It was terrible,” his wife Judith Snider told CTV News. “But we finally decided that what we had to do was to live each day not to look forward to the end, but to look forward to tomorrow.”
And yet, a year later, Snider is alive -- transformed, even -- and his non-Hodgkins lymphoma is in remission. His second chance is all thanks to a promising, Canadian-run program for cancer treatment called CAR T-cell therapy.
Snider became one of the first patients to participate in a national research program that is assessing whether this experimental treatment can be done safely in Canada and cheaper than in the U.S., where costs can run upwards of half a million dollars per patient.
“I think I am a pretty successful lab rat,” Snider, who previously endured chemotherapy treatments and a stem cell transplant, said in an interview.
“Thirty days after treatment, the lymphoma was gone. So how can you not be happy about that?”
WHAT IS CAR T-CELL THERAPY?
CAR T-cell therapy is a type of gene therapy that trains or “engineers” a patient’s own immune system to recognize cancerous cells. A type of white blood cell, called a T-cell, is a key component of a body’s immune system. They are developed from stem cells in the bone marrow and help fight infection and disease by searching and targeting specific foreign substances, known as antigens, in the body.
The protein receptors on T cells bind to the protein antigens on the surfaces of foreign particles that fit those receptors, like a lock and key. The foreign substance is eradicated once their antigens are bound to a T-cell. But blood cancer cells are normal cells that undergo mutations, so they are not recognized as a foreign threat to the body. In other words, T-cells generally do not have the right receptor “key” to fit with the antigens of a cancer cell.
CAR T-cell therapy modifies the cells so they are able to identify the cancer cells and destroy them. It’s a labour-intensive process that involves taking blood from a patient and separating the T-cells. Then scientists add a gene to the cells that gives them instructions to develop an artificial receptor called a chimeric antigen receptor, or CAR.
“We actually take the T-cells out and we modify them in the lab and put them back into the patient. So now they're able to recognize the cancer and kill it off,” explained Dr. Kevin Hay, Medical Director for Clinical Cell Therapy with BC Cancer.
“I think we're just at the cusp of really understanding what this is going to do for patients in the future.”
The therapy is a labour-intensive process -- Snider's cells were shipped to Victoria, B.C to be processed in a special lab facility, then shipped back to Ottawa about a week later, where they were infused back into his body.
The treatment is still being studied, but is already available for some cancers in the U.S. and Canada at a steep price.
Researchers began trials in Canada in 2019 to see if it could be done domestically at a lower cost, highlighting the importance of having key medical production and therapies available in Canada.
“We knew we had to do domestic manufacturing and if we've learned anything from COVID-19, it's that domestic capability is really important when it comes to science and medicine, and this is a perfect example of that,” said Dr. Natasha Kekre, a hematologist and lead researcher on the trail based at the Ottawa Hospital.
Progress was impacted slightly by the pandemic, but Snider was fortunate enough to participate and is the first patient to come forward to discuss their experience and why he hopes the program will expand across Canada to help others dealing with otherwise untreatable forms of cancer.
Scientists are hoping to release more data in the coming months -- more than 20 patients have been treated so far, according to Dr. Kekre.
“This is hopefully just the beginning for us. So this first trial was a foundation to prove that we could actually manufacture T cells, that we could do this in a clinical trial. And so this trial will remain open for patients who are in need,” she said.
“So absolutely we feel like we’re opening a door.”
A LONG CANCER JOURNEY
Snider's first experience with cancer treatment was more than a decade ago, in 2010, when he underwent a powerful and aggressive chemotherapy regimen that helped him stay cancer-free for six years.
But the treatment was so harsh that when his cancer came back in 2016, doctors told him he could not go through that kind of chemotherapy again. Instead, Snider underwent a stem cell transplant, which gave him another four years without cancer, until April 2020.
This time the outlook was grim, so doctors decided to try and get him into the CAR T-cell trials that started just before the pandemic hit. The study was specifically for patients with acute lymphoblastic leukemia and non-Hodgkin’s lymphoma who were not responding to other treatments.
Snider said the entire process was a “walk in the park” compared to what he had gone through before. He was given a mild chemotherapy treatment for three days while his T-cells were being modified in a lab on the other side of the country.
“[The T-cells] went to work right away. There's a period of time where there's a lot going on inside fighting each other and that sort of thing. You don't feel great or you don't really know how you feel,” Snider described. The treatment was met with “outstanding success.”
“And in 30 days, there was no lymphoma. I couldn't believe it.”
For Dr. Kekre, the results bring hope. Snider has done quite well and does not have any evidence of lymphoma at the moment, she said.
“I'm unfortunately in a business where I often have to give bad news, and it is really motivating and exciting to be able to offer therapies to patients who didn't have options and to make them better,” she said.
The trial is currently at the stage where scientists are making sure the product remains safe. Side-effects can include neurotoxicity, which harms the nervous system, and cytokine release syndrome, which triggers an acute system-wide inflammatory response that can result in organs not functioning properly. But so far researchers have, for the most part, been able to manage and reverse any side effects.
With such promising outcomes for patients who otherwise had no options left, researchers are talking about expanding these studies across Canada and to other forms of cancer.
For now, the Ottawa Hospital is the only one in Canada that can make the virus used to create the CAR-T cells and the Lab in Victoria the only facility equipped to make these cell modifications.
But doctors plan to expand, with Ottawa set to start processing the CAR-T cells as well as open the experimental therapy to more patients.
“I think it’s really going to be revolutionary with how we treat cancer in the future, not just blood cancers, but all cancers,” said Dr. Hay.
Today, Snider is healthy and strong, even able to chop wood at his home near Ottawa. He and his wife Judith, a retired federal judge, are enjoying life anew.
“It certainly has given us a future that we didn’t know we had,” she said.
The treatment not only bought Snider extra time, but also significantly improved his quality of life.
“What was given to me is practically a normal life,” he added.
“It's really just transformed, not just extended, but transformed my life.”
COVID-19 COVERAGE
CTVNews.ca Top Stories
Beyonce becomes most decorated artist in Grammys history; Harry Styles wins album of the year
Harry Styles won album of the year at Sunday's Grammy Awards, taking home the top honour on a night that Beyoncé dominated and became the ceremony's most decorated artist. Beyonce won her 32nd award, breaking a 26-year-old record. But as in years past, the album of the year honour eluded her.

First tank sent by Canada for Ukrainian forces arrives in Poland
The first of the Leopard 2 tanks Canada is donating to Ukrainian forces has arrived in Poland.
Advocates come together to help sailors stuck for months on tugboats in Quebec port
Groups that advocate for seafarers are expressing concern for 11 sailors who are spending a harsh Quebec winter aboard three tugboats that have been detained for months in the port of Trois-Rivières.
At least 100 dead as powerful 7.8 earthquake hits Turkiye, Syria
A powerful 7.8 magnitude earthquake hit southeast Turkiye and Syria early Monday, toppling buildings and sending panicked residents pouring outside in a cold winter night. At least 100 were killed, and the toll was expected to rise.
Charles Kimbrough, best known for role in 'Murphy Brown,' dies at 86
Charles Kimbrough, a Tony- and Emmy-nominated actor who played a straight-laced news anchor opposite Candice Bergen on “Murphy Brown,” died Jan. 11 in Culver City, California. He was 86.
‘Natural power’: 17-year-old undefeated Quebec boxer gears up for Canada Games
She started throwing punches to get exercise during the COVID-19 pandemic, but now 17-year-old Talia Birch is gearing up to compete in the Canada Games as it opens up to female boxers for the first time
31,000 cards: Montreal woman passing along father's extensive collection of Expos baseball cards
A Montreal woman is passing along her father's extensive collection of over 31,000 Expos baseball cards. April Whitzman's father, Steve Whitzman, collected the cards from 1969 to 2016. A huge Expos fan, he's got every player covered.
Canadians Drake, Michael Buble, Tobias Jesso Jr. among early Grammy winners
Singer-songwriter Tobias Jesso Jr. became a first-time Grammy Award winner at the pre-broadcast ceremony where fellow Canadians Michael Buble and Drake also picked up trophies.
New study highlights increasing prevalence of muscle dysmorphia among Canadian boys, young men
Canadian researchers are drawing attention to the increasing prevalence of 'a pathological pursuit of muscularity' among Canadian boys and young men, with a new study that found one in four were at risk of developing what's known as muscle dysmorphia.